US2844579A
(en)
|
|
1958-07-22 |
|
Process for thiamine monomtrate |
US3180859A
(en)
|
1962-12-05 |
1965-04-27 |
Upjohn Co |
Derivatives of decoyinine and process for preparing same
|
US3431252A
(en)
|
1966-04-01 |
1969-03-04 |
Merck & Co Inc |
5,5-dialkyl-d-ribofuranosyl purine compounds and intermediates
|
US3480613A
(en)
|
1967-07-03 |
1969-11-25 |
Merck & Co Inc |
2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
|
US3816399A
(en)
|
1970-07-14 |
1974-06-11 |
Univ Bradford |
1-amine nucleosides
|
GB1319303A
(en)
|
1970-07-14 |
1973-06-06 |
Univ Bradford |
Sugar derivatives
|
US3872098A
(en)
|
1972-10-10 |
1975-03-18 |
Syntex Inc |
1,n{hu 6{b ethenoadenosine cyclophosphate compounds
|
US3872084A
(en)
|
1972-10-10 |
1975-03-18 |
Syntex Inc |
Purine nucleoside 3,5-cyclicphosphate compounds
|
US4093714A
(en)
|
1974-03-15 |
1978-06-06 |
Icn Pharmaceuticals, Inc. |
9β-D-Arabinofuranosylpurine nucleotides and method of use
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
PL144471B1
(en)
|
1985-04-22 |
1988-05-31 |
Polska Akad Nauk Centrum |
Method of obtaining novel 3',5'-cyclic adensine dithiophosphate
|
EP0206497B1
(en)
|
1985-05-15 |
1994-07-20 |
The Wellcome Foundation Limited |
Therapeutic nucleosides and their preparation
|
JPH0446124Y2
(es)
|
1986-02-25 |
1992-10-29 |
|
|
AU8276187A
(en)
|
1986-10-31 |
1988-05-25 |
Warner-Lambert Company |
Selected n6-substituted adenosines having selective a2 binding activity
|
IL86007A0
(en)
|
1987-04-09 |
1988-09-30 |
Wellcome Found |
6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
|
US4885739A
(en)
|
1987-11-13 |
1989-12-05 |
Dsc Communications Corporation |
Interprocessor switching network
|
DE3824110A1
(de)
|
1988-07-15 |
1990-01-18 |
Max Planck Gesellschaft |
Verfahren zur herstellung und reinigung von an ihrem 5'-ende phosphorylierten oligo- und jpolynukleotidsequenzen und reagenz zur durchfuehrung des verfahrens
|
HUT51643A
(en)
|
1988-11-21 |
1990-05-28 |
Syntex Inc |
Process for producing antiviral agents and pharmaceutical compositions comprising same as active ingredient
|
US5646128A
(en)
|
1989-09-15 |
1997-07-08 |
Gensia, Inc. |
Methods for treating adenosine kinase related conditions
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
GB9009861D0
(en)
|
1990-05-02 |
1990-06-27 |
Glaxo Group Ltd |
Chemical compounds
|
US6087482A
(en)
|
1990-07-27 |
2000-07-11 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
WO1992012718A1
(en)
|
1991-01-23 |
1992-08-06 |
Gensia, Inc. |
Adenosine kinase inhibitors
|
RU2126255C1
(ru)
|
1991-05-15 |
1999-02-20 |
Йель Юниверсити |
Способ получения противоопухолевого эффекта у млекопитающих
|
IT1249732B
(it)
|
1991-11-26 |
1995-03-09 |
Angeletti P Ist Richerche Bio |
Oligonucleotidi antisenso.
|
US6469158B1
(en)
|
1992-05-14 |
2002-10-22 |
Ribozyme Pharmaceuticals, Incorporated |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
US5977343A
(en)
|
1992-05-14 |
1999-11-02 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
US5686599A
(en)
|
1992-05-14 |
1997-11-11 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
US5804683A
(en)
|
1992-05-14 |
1998-09-08 |
Ribozyme Pharmaceuticals, Inc. |
Deprotection of RNA with alkylamine
|
US5714383A
(en)
|
1992-05-14 |
1998-02-03 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treating chronic myelogenous leukemia
|
US5625056A
(en)
|
1992-05-26 |
1997-04-29 |
Biolog Life Science Institute |
Derivatives of cyclic guanosine-3',5'-monophosphorothioate
|
WO1993025566A1
(en)
|
1992-06-18 |
1993-12-23 |
Jyoti Chattopadhyaya |
Deuterated nucleosides
|
US5811300A
(en)
|
1992-12-07 |
1998-09-22 |
Ribozyme Pharmaceuticals, Inc. |
TNF-α ribozymes
|
US5616488A
(en)
|
1992-12-07 |
1997-04-01 |
Ribozyme Pharmaceuticals, Inc. |
IL-5 targeted ribozymes
|
US5658780A
(en)
|
1992-12-07 |
1997-08-19 |
Ribozyme Pharmaceuticals, Inc. |
Rel a targeted ribozymes
|
US5837542A
(en)
|
1992-12-07 |
1998-11-17 |
Ribozyme Pharmaceuticals, Inc. |
Intercellular adhesion molecule-1 (ICAM-1) ribozymes
|
JPH06228186A
(ja)
|
1993-01-29 |
1994-08-16 |
Yamasa Shoyu Co Ltd |
2’−デオキシ−(2’s)−アルキルピリミジンヌクレオシド誘導体
|
IL108523A0
(en)
|
1993-02-03 |
1994-05-30 |
Gensia Inc |
Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
|
CA2159632A1
(en)
|
1993-03-31 |
1994-10-13 |
Ashis Kumar Saha |
Novel 5'-substituted nucleosides and oligomers produced therefrom
|
HU9501978D0
(en)
|
1993-03-31 |
1995-09-28 |
Sterling Winthorp Inc |
Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
|
GB9311682D0
(en)
|
1993-06-05 |
1993-07-21 |
Ciba Geigy Ag |
Chemical compounds
|
US6491905B1
(en)
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
US5552311A
(en)
|
1993-09-14 |
1996-09-03 |
University Of Alabama At Birmingham Research Foundation |
Purine nucleoside phosphorylase gene therapy for human malignancy
|
US6017896A
(en)
|
1993-09-14 |
2000-01-25 |
University Of Alabama Research Foundation And Southern Research Institute |
Purine nucleoside phosphorylase gene therapy for human malignancy
|
US6156501A
(en)
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
JPH09504297A
(ja)
|
1993-10-27 |
1997-04-28 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
2′−アミドおよび2′−ペプチド修飾オリゴヌクレオチド
|
DE4341161A1
(de)
|
1993-12-02 |
1995-06-08 |
Michael Prof Dr Zeppezauer |
Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
|
AU1436995A
(en)
|
1993-12-30 |
1995-07-17 |
Chemgenes Corporation |
Synthesis of propargyl modified nucleosides and phosphoramidites and their incorporation into defined sequence oligonucleotides
|
US5902880A
(en)
|
1994-08-19 |
1999-05-11 |
Ribozyme Pharmaceuticals, Inc. |
RNA polymerase III-based expression of therapeutic RNAs
|
US5631359A
(en)
|
1994-10-11 |
1997-05-20 |
Ribozyme Pharmaceuticals, Inc. |
Hairpin ribozymes
|
US5639647A
(en)
|
1994-03-29 |
1997-06-17 |
Ribozyme Pharmaceuticals, Inc. |
2'-deoxy-2'alkylnucleotide containing nucleic acid
|
US5693532A
(en)
|
1994-11-04 |
1997-12-02 |
Ribozyme Pharmaceuticals, Inc. |
Respiratory syncytial virus ribozymes
|
US5620676A
(en)
|
1994-03-08 |
1997-04-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
Biologically active ATP analogs
|
US6639061B1
(en)
|
1999-07-07 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate oligomers and related compounds
|
US5871918A
(en)
|
1996-06-20 |
1999-02-16 |
The University Of North Carolina At Chapel Hill |
Electrochemical detection of nucleic acid hybridization
|
US5580967A
(en)
|
1994-05-13 |
1996-12-03 |
The Scripps Research Institute |
Optimized catalytic DNA-cleaving ribozymes
|
US6063566A
(en)
|
1994-05-13 |
2000-05-16 |
The Scripps Research Institute |
Catalytic RNA molecules
|
GB9417746D0
(en)
|
1994-09-03 |
1994-10-19 |
Ciba Geigy Ag |
Chemical compounds
|
GB9417938D0
(en)
|
1994-09-06 |
1994-10-26 |
Ciba Geigy Ag |
Compounds
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
US7141665B1
(en)
|
1998-04-29 |
2006-11-28 |
The Scripps Research Institute |
Enzymatic DNA molecules
|
US5807718A
(en)
|
1994-12-02 |
1998-09-15 |
The Scripps Research Institute |
Enzymatic DNA molecules
|
DK0806956T3
(da)
|
1995-02-01 |
2003-01-06 |
Resprotect Gmbh |
Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
AU4931196A
(en)
|
1995-03-24 |
1996-10-16 |
Christian Noe |
Nucleic acid polyester polyamides
|
US6132971A
(en)
|
1995-06-27 |
2000-10-17 |
The University Of North Carolina At Chapel Hill |
Microelectronic device
|
US6361951B1
(en)
|
1995-06-27 |
2002-03-26 |
The University Of North Carolina At Chapel Hill |
Electrochemical detection of nucleic acid hybridization
|
US5968745A
(en)
|
1995-06-27 |
1999-10-19 |
The University Of North Carolina At Chapel Hill |
Polymer-electrodes for detecting nucleic acid hybridization and method of use thereof
|
US6004939A
(en)
|
1995-07-06 |
1999-12-21 |
Ctrc Research Foundation Board Of Regents |
Methods for modulation and inhibition of telomerase
|
US20010011075A1
(en)
|
1999-02-05 |
2001-08-02 |
Leroy B Townsend |
5'-substituted-ribofuranosyl benzimidazoles as antiviral agents
|
DE69637256T2
(de)
|
1996-01-16 |
2008-06-19 |
Sirna Therapeutics, Inc., Boulder |
Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
|
US5767097A
(en)
|
1996-01-23 |
1998-06-16 |
Icn Pharmaceuticals, Inc. |
Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
|
EP0799834A1
(en)
|
1996-04-04 |
1997-10-08 |
Novartis AG |
Modified nucleotides
|
US20040171028A1
(en)
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US20050032067A1
(en)
|
2002-11-05 |
2005-02-10 |
Prakash Thazha P. |
Non-phosphorous-linked oligomeric compounds and their use in gene modulation
|
US20040171032A1
(en)
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Non-phosphorous-linked oligomeric compounds and their use in gene modulation
|
US20050042647A1
(en)
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
WO1998000434A1
(en)
|
1996-06-28 |
1998-01-08 |
Novartis Ag |
Modified oligonucleotides
|
IL129126A0
(en)
|
1996-10-16 |
2000-02-17 |
Icn Pharmaceuticals |
Monocyclic l-nucleosides analogs and uses thereof
|
NZ505531A
(en)
|
1996-10-16 |
2001-08-31 |
Icn Pharmaceuticals |
7-Propyl-8-oxo-alpha or beta-L-guanine alpha or beta-L-nucleoside
|
IL129407A0
(en)
|
1996-10-18 |
2000-02-17 |
Vertex Pharma |
Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
|
US6887707B2
(en)
|
1996-10-28 |
2005-05-03 |
University Of Washington |
Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
|
JP2001525797A
(ja)
|
1996-10-28 |
2001-12-11 |
ザ ユニバーシティ オブ ワシントン |
ウイルスrnaへのミスコーディングリボヌクレオシドアナログの組込みによるウイルス変異の誘導
|
US7078391B2
(en)
|
1997-02-10 |
2006-07-18 |
Inspire Pharmaceuticals, Inc. |
Method of treating edematous retinal disorders
|
US20030144489A1
(en)
|
1997-06-09 |
2003-07-31 |
Alex Burgin |
Method for screening nucleic acid catalysts
|
NZ503263A
(en)
|
1997-08-11 |
2002-10-25 |
Boehringer Ingelheim Ca Ltd |
Hepatitis C NS3 protease inhibitor peptides and peptide analogues
|
ES2241157T3
(es)
|
1997-08-11 |
2005-10-16 |
Boehringer Ingelheim (Canada) Ltd. |
Peptidos inhibidores de la hepatitis c.
|
AU9210498A
(en)
|
1997-08-29 |
1999-03-16 |
Gilead Sciences, Inc. |
5',5'-linked oligomers having anti-thrombin activity
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
US6232463B1
(en)
|
1997-10-09 |
2001-05-15 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US6703374B1
(en)
|
1997-10-30 |
2004-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Nucleosides for imaging and treatment applications
|
US20030004122A1
(en)
|
1997-11-05 |
2003-01-02 |
Leonid Beigelman |
Nucleotide triphosphates and their incorporation into oligonucleotides
|
US6528640B1
(en)
|
1997-11-05 |
2003-03-04 |
Ribozyme Pharmaceuticals, Incorporated |
Synthetic ribonucleic acids with RNAse activity
|
US6482932B1
(en)
|
1997-11-05 |
2002-11-19 |
Ribozyme Pharmaceuticals, Incorporated |
Nucleoside triphosphates and their incorporation into oligonucleotides
|
US6617438B1
(en)
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
US6015703A
(en)
|
1998-03-10 |
2000-01-18 |
Iogen Corporation |
Genetic constructs and genetically modified microbes for enhanced production of beta-glucosidase
|
WO1999055857A2
(en)
|
1998-04-29 |
1999-11-04 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside triphosphates and their incorporation into ribozymes
|
US6030957A
(en)
|
1998-06-29 |
2000-02-29 |
Wayne Hughes Institute |
Aryl phosphate derivatives of d4T having anti-HIV activity
|
US7091315B1
(en)
|
1998-07-15 |
2006-08-15 |
Human Genome Sciences, Inc. |
Protein HDPBQ71
|
AU756627B2
(en)
|
1998-07-27 |
2003-01-16 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Diketoacid-derivatives as inhibitors of polymerases
|
AR022061A1
(es)
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
WO2000014263A2
(en)
|
1998-09-03 |
2000-03-16 |
Board Of Regents, The University Of Texas System |
Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them
|
US6458945B1
(en)
|
1998-10-01 |
2002-10-01 |
Variagenics, Inc. |
Method for analyzing polynucleotides
|
US6440705B1
(en)
|
1998-10-01 |
2002-08-27 |
Vincent P. Stanton, Jr. |
Method for analyzing polynucleotides
|
US6566059B1
(en)
|
1998-10-01 |
2003-05-20 |
Variagenics, Inc. |
Method for analyzing polynucleotides
|
CA2252144A1
(en)
|
1998-10-16 |
2000-04-16 |
University Of Alberta |
Dual action anticancer prodrugs
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
JP2002540080A
(ja)
|
1999-03-19 |
2002-11-26 |
パーカー ヒューズ インスティテュート |
ゲルミクロ乳濁液製剤
|
UA74546C2
(en)
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6569630B1
(en)
|
1999-07-02 |
2003-05-27 |
Conceptual Mindworks, Inc. |
Methods and compositions for aptamers against anthrax
|
US20040023265A1
(en)
|
1999-07-02 |
2004-02-05 |
Jeevalatha Vivekananda |
Methods and compositions for nucleic acid ligands against Shiga toxin and/or Shiga-like toxin
|
WO2001009318A1
(fr)
|
1999-07-29 |
2001-02-08 |
Helix Research Institute |
Genes associes au cancer du foie
|
CN1384834A
(zh)
|
1999-08-27 |
2002-12-11 |
Icn药品公司 |
吡咯并[2,3-d]嘧啶核苷类似物
|
US6831069B2
(en)
|
1999-08-27 |
2004-12-14 |
Ribapharm Inc. |
Pyrrolo[2,3-d]pyrimidine nucleoside analogs
|
US6770666B2
(en)
|
1999-12-27 |
2004-08-03 |
Japan Tobacco Inc. |
Fused-ring compounds and use thereof as drugs
|
AU763356C
(en)
|
1999-12-27 |
2004-08-26 |
Japan Tobacco Inc. |
Fused-ring compounds and use thereof as drugs
|
US6649750B1
(en)
|
2000-01-05 |
2003-11-18 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotide compounds
|
US6495677B1
(en)
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
KR20030005197A
(ko)
|
2000-02-18 |
2003-01-17 |
샤이어 바이오켐 인코포레이티드 |
뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법
|
US7235649B2
(en)
|
2000-03-24 |
2007-06-26 |
Duke University |
Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
|
JP2003528886A
(ja)
|
2000-03-24 |
2003-09-30 |
デューク・ユニバーシティ |
Crp94−リガンド相互作用の特徴付けおよびそれに関連する精製、スクリーニングおよび治療法
|
FR2808797A1
(fr)
|
2000-05-09 |
2001-11-16 |
Hoechst Marion Roussel Inc |
Nouveaux derives de l'uridine, leur procede de preparation et leur application comme medicaments
|
EP1292310A1
(en)
|
2000-05-10 |
2003-03-19 |
SmithKline Beecham Corporation |
Novel anti-infectives
|
AU2001274888A1
(en)
|
2000-05-19 |
2001-12-03 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
KR100854398B1
(ko)
|
2000-05-26 |
2008-08-26 |
이데닉스 (케이만) 리미티드 |
베타-l-2'-데옥시-뉴클레오사이드를 이용한 델타형 간염바이러스 감염의 치료방법
|
WO2001092581A2
(en)
|
2000-05-26 |
2001-12-06 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
NZ547204A
(en)
|
2000-05-26 |
2008-01-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
US6974667B2
(en)
|
2000-06-14 |
2005-12-13 |
Gene Logic, Inc. |
Gene expression profiles in liver cancer
|
US6815542B2
(en)
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
AU6842701A
(en)
|
2000-06-16 |
2002-01-14 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
US20030207271A1
(en)
|
2000-06-30 |
2003-11-06 |
Holwitt Eric A. |
Methods and compositions for biological sensors
|
UA72612C2
(en)
|
2000-07-06 |
2005-03-15 |
|
Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
|
GB0017676D0
(en)
|
2000-07-19 |
2000-09-06 |
Angeletti P Ist Richerche Bio |
Inhibitors of viral polymerase
|
US20030166064A1
(en)
|
2000-08-03 |
2003-09-04 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of colon cancer
|
US20030008841A1
(en)
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
AU2001290548A1
(en)
|
2000-09-11 |
2002-03-26 |
Hyseq, Inc. |
Novel nucleic acids and polypeptides
|
AU2001296301A1
(en)
|
2000-09-26 |
2002-04-08 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
CN1133642C
(zh)
|
2000-10-09 |
2004-01-07 |
清华大学 |
核苷5’-硫代磷酰氨基酸酯化合物
|
EP2145965A1
(en)
|
2000-10-18 |
2010-01-20 |
Pharmasset, Inc. |
Multiplex quantification of nucleic acids in diseased cells
|
AU2002246519A1
(en)
|
2000-11-20 |
2002-08-06 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of colon cancer
|
WO2002060926A2
(en)
|
2000-11-20 |
2002-08-08 |
Bristol-Myers Squibb Company |
Hepatitis c tripeptide inhibitors
|
MXPA03006514A
(es)
|
2001-01-22 |
2004-12-02 |
Merck & Co Inc |
Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
AU2002251841A1
(en)
|
2001-01-30 |
2002-08-12 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of pancreatic cancer
|
WO2002069903A2
(en)
|
2001-03-06 |
2002-09-12 |
Biocryst Pharmaceuticals, Inc. |
Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
|
CA2441832A1
(en)
|
2001-03-21 |
2002-12-27 |
Human Genome Sciences, Inc. |
Human secreted proteins
|
WO2002097031A2
(en)
|
2001-03-28 |
2002-12-05 |
Incyte Genomics, Inc. |
Molecules for diagnostics and therapeutics
|
US6995148B2
(en)
|
2001-04-05 |
2006-02-07 |
University Of Pittsburgh |
Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
|
CN1186456C
(zh)
|
2001-04-30 |
2005-01-26 |
曹卫 |
通用模板核酸检测方法和试剂盒
|
EP1256628A3
(en)
|
2001-05-10 |
2003-03-19 |
Agouron Pharmaceuticals, Inc. |
Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
|
CN101113160A
(zh)
|
2001-05-16 |
2008-01-30 |
米珍尼克斯公司 |
基于核酸的化合物及其使用方法
|
US20030170891A1
(en)
|
2001-06-06 |
2003-09-11 |
Mcswiggen James A. |
RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
EP1390385A4
(en)
|
2001-05-29 |
2004-11-24 |
Sirna Therapeutics Inc |
MODULATION OF DISEASES AND DISEASES OF THE FEMALE REPRODUCTION SYSTEM BASED ON NUCLEIC ACID
|
AR036081A1
(es)
|
2001-06-07 |
2004-08-11 |
Smithkline Beecham Corp |
Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
|
ATE438637T1
(de)
|
2001-06-11 |
2009-08-15 |
Virochem Pharma Inc |
Thiophenderivate als antivirale mittel gegen flavivirus-infektion
|
CA2449999C
(en)
|
2001-06-11 |
2012-07-31 |
Shire Biochem Inc. |
Compounds and methods for the treatment or prevention of flavivirus infections
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
AR035543A1
(es)
|
2001-06-26 |
2004-06-16 |
Japan Tobacco Inc |
Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
|
EP2335700A1
(en)
|
2001-07-25 |
2011-06-22 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C virus polymerase inhibitors with a heterobicylic structure
|
EP1478772A2
(en)
|
2001-08-14 |
2004-11-24 |
The General Hospital Corporation |
Nucleic acid and amino acid sequences involved in pain
|
AU2002329784A1
(en)
|
2001-08-17 |
2003-03-03 |
Incyte Genomics, Inc. |
Molecules for disease detection and treatment
|
WO2003016572A1
(en)
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
Oligonucleotide therapeutics for treating hepatitis c virus infections
|
CN1133641C
(zh)
|
2001-08-24 |
2004-01-07 |
清华大学 |
一种含有3'叠氮胸苷的硫代磷酰氨基酸酯化合物及其制备方法
|
CN1159332C
(zh)
|
2001-08-24 |
2004-07-28 |
清华大学 |
一种硫代磷酰氨基酸酯化合物及其制备方法
|
CN1186457C
(zh)
|
2001-08-29 |
2005-01-26 |
曹卫 |
均相基因矩阵
|
WO2003029271A2
(en)
|
2001-09-24 |
2003-04-10 |
Nuvelo |
Novel nucleic acids and polypeptides
|
US20030134853A1
(en)
|
2001-09-26 |
2003-07-17 |
Priestley Eldon Scott |
Compounds useful for treating hepatitis C virus
|
AU2002347778A1
(en)
|
2001-09-28 |
2003-05-26 |
Incyte Genomics, Inc. |
Enzymes
|
WO2003031419A1
(en)
|
2001-10-09 |
2003-04-17 |
3-Dimensional Pharmaceuticals, Inc. |
Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
|
CA2462785A1
(en)
|
2001-10-19 |
2003-04-24 |
Incyte Genomics, Inc. |
Kinases and phosphatases
|
AU2002348414B2
(en)
|
2001-10-24 |
2009-10-01 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
|
US7037718B2
(en)
|
2001-10-26 |
2006-05-02 |
Cornell Research Foundation, Inc. |
Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
|
US7488598B2
(en)
|
2001-10-26 |
2009-02-10 |
Cornell Center For Technology Enterprise And Commercialization |
Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
|
CA2462660A1
(en)
|
2001-10-29 |
2003-05-08 |
Incyte Genomics, Inc. |
Nucleic acid-associated proteins
|
AU2002351077A1
(en)
|
2001-11-05 |
2003-05-19 |
Exiqon A/S |
Oligonucleotides modified with novel alpha-l-rna analogues
|
WO2003039348A2
(en)
|
2001-11-09 |
2003-05-15 |
Incyte Genomics Inc. |
Intracellular signaling molecules
|
EP1504099A4
(en)
|
2001-12-10 |
2006-05-10 |
Nuvelo Inc |
NEW NUCLEIC ACIDS AND POLYPEPTIDES
|
AU2002340387A1
(en)
|
2001-12-17 |
2003-06-30 |
Ribapharm Inc. |
Cytidine libraries and compounds synthesized by solid-phase combinatorial strategies
|
AU2002358273A1
(en)
|
2001-12-19 |
2003-07-09 |
Incyte Corporation |
Nucleic acid-associated proteins
|
WO2003072602A2
(en)
|
2001-12-20 |
2003-09-04 |
Cellzome Ag |
Protein complexes and methods for their use
|
WO2003062376A2
(en)
|
2002-01-16 |
2003-07-31 |
Incyte Genomics, Inc. |
Molecules for diagnostics and therapeutics
|
AU2003205174A1
(en)
|
2002-01-17 |
2003-09-02 |
Incyte Genomics, Inc. |
Molecules for disease detection and treatment
|
WO2003062256A1
(en)
|
2002-01-17 |
2003-07-31 |
Ribapharm Inc. |
2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
|
AU2002341942A1
(en)
|
2002-01-17 |
2003-09-02 |
Ribapharm Inc. |
Sugar modified nucleosides as viral replication inhibitors
|
AU2003207628A1
(en)
|
2002-01-18 |
2003-09-02 |
Incyte Corporation |
Structural and cytoskeleton-associated proteins
|
WO2003063688A2
(en)
|
2002-01-25 |
2003-08-07 |
Incyte Corporation |
Protein modification and maintenance molecules
|
US20050042632A1
(en)
|
2002-02-13 |
2005-02-24 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for nucleic acids
|
US20080207542A1
(en)
|
2002-03-26 |
2008-08-28 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
WO2003072729A2
(en)
|
2002-02-22 |
2003-09-04 |
Incyte Corporation |
Enzymes
|
AU2003217863B9
(en)
|
2002-02-28 |
2009-10-29 |
Biota Scientific Management Pty Ltd |
Nucleotide mimics and their prodrugs
|
EP1481088B1
(en)
|
2002-03-01 |
2008-09-17 |
Integrated Dna Technologies, Inc. |
Polynomial amplification of nucleic acids
|
AU2003217992A1
(en)
|
2002-03-06 |
2003-09-22 |
Incyte Corporation |
Nucleic acid-associated proteins
|
WO2003077875A2
(en)
|
2002-03-15 |
2003-09-25 |
Incyte Corporation |
Proteins associated with growth, differentiation, and death
|
WO2003083085A2
(en)
|
2002-03-28 |
2003-10-09 |
Incyte Corporation |
Transporters and ion channels
|
WO2003083084A2
(en)
|
2002-03-29 |
2003-10-09 |
Incyte Corporation |
Protein modification and maintenance molecules
|
AU2003220607A1
(en)
|
2002-03-29 |
2003-10-13 |
Incyte Corporation |
Enzymes
|
WO2003087300A2
(en)
|
2002-04-05 |
2003-10-23 |
Incyte Corporation |
Secreted proteins
|
US20030190626A1
(en)
|
2002-04-09 |
2003-10-09 |
Vasulinga Ravikumar |
Phosphorothioate monoester modified oligomers
|
JP2005535574A
(ja)
|
2002-04-11 |
2005-11-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、特にhcvns3−ns4aプロテアーゼのインヒビター
|
US20060074035A1
(en)
*
|
2002-04-17 |
2006-04-06 |
Zhi Hong |
Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections
|
US20050288258A1
(en)
|
2002-04-23 |
2005-12-29 |
Diana Guy D |
Compounds, compositions and methods for treating or preventing viral infections and associated diseases
|
WO2003093439A2
(en)
|
2002-04-29 |
2003-11-13 |
Incyte Corporation |
Enzymes
|
EP1501850A2
(en)
|
2002-05-06 |
2005-02-02 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis c virus infection
|
WO2003094848A2
(en)
|
2002-05-10 |
2003-11-20 |
Incyte Corporation |
Nucleic acid-associated proteins
|
FR2840318B1
(fr)
|
2002-05-29 |
2004-12-03 |
Quoc Kiet Pham |
Nouveaux sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih
|
EP1511757B1
(en)
|
2002-06-07 |
2015-11-04 |
Universitair Medisch Centrum Utrecht |
New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
|
WO2004001008A2
(en)
|
2002-06-21 |
2003-12-31 |
Incyte Corporation |
Kinases and phosphatases
|
WO2004003162A2
(en)
|
2002-06-28 |
2004-01-08 |
Incyte Corporation |
Enzymes
|
AU2003248748A1
(en)
|
2002-06-28 |
2004-01-19 |
Idenix (Cayman) Limited |
2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
PL374792A1
(en)
|
2002-06-28 |
2005-10-31 |
Idenix (Cayman) Limited |
2' and 3'-nucleoside prodrugs for treating flaviviridae infections
|
NZ537662A
(en)
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
AU2003268023A1
(en)
|
2002-07-23 |
2004-02-09 |
Incyte Corporation |
Protein modification and maintenance molecules
|
AU2003259735A1
(en)
|
2002-08-08 |
2004-02-25 |
Sirna Therapeutics, Inc. |
Small-mer compositions and methods of use
|
WO2004014313A2
(en)
|
2002-08-12 |
2004-02-19 |
Bristol-Myers Squibb Company |
Combination pharmaceutical agents as inhibitors of hcv replication
|
GB0221694D0
(en)
|
2002-09-18 |
2002-10-30 |
Glaxo Group Ltd |
Compounds
|
EP1545558A4
(en)
|
2002-09-24 |
2010-02-17 |
Koronis Pharmaceuticals Inc |
1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
|
US20070207973A1
(en)
|
2002-09-24 |
2007-09-06 |
Koronis Pharmaceuticals, Incorporated |
1,3,5-Triazines for Treatment of Viral Diseases
|
US7094768B2
(en)
|
2002-09-30 |
2006-08-22 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis C virus infection
|
KR20050088079A
(ko)
|
2002-11-15 |
2005-09-01 |
이데닉스 (케이만) 리미티드 |
2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
|
WO2004050899A2
(en)
|
2002-12-03 |
2004-06-17 |
Archemix Corporation |
Method for in vitro selection of 2’-substituted nucleic acids
|
US20050037394A1
(en)
|
2002-12-03 |
2005-02-17 |
Keefe Anthony D. |
Method for in vitro selection of 2'-substituted nucleic acids
|
CA2509687C
(en)
|
2002-12-12 |
2012-08-14 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
PT1992635E
(pt)
|
2002-12-23 |
2012-03-20 |
Dynavax Tech Corp |
Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
|
AR043006A1
(es)
|
2003-02-12 |
2005-07-13 |
Merck & Co Inc |
Proceso para preparar ribonucleosidos ramificados
|
WO2004080466A1
(en)
|
2003-03-07 |
2004-09-23 |
Ribapharm Inc. |
Cytidine analogs and methods of use
|
ES2381548T3
(es)
|
2003-04-11 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A
|
WO2004092161A1
(en)
|
2003-04-11 |
2004-10-28 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
US20050261237A1
(en)
|
2003-04-25 |
2005-11-24 |
Boojamra Constantine G |
Nucleoside phosphonate analogs
|
US7427636B2
(en)
|
2003-04-25 |
2008-09-23 |
Gilead Sciences, Inc. |
Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US20090247488A1
(en)
|
2003-04-25 |
2009-10-01 |
Carina Cannizzaro |
Anti-inflammatory phosphonate compounds
|
ATE490788T1
(de)
|
2003-04-25 |
2010-12-15 |
Gilead Sciences Inc |
Antivirale phosphonate analoge
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
CN101410120A
(zh)
|
2003-04-25 |
2009-04-15 |
吉里德科学公司 |
抗炎的膦酸酯化合物
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
US20040259934A1
(en)
|
2003-05-01 |
2004-12-23 |
Olsen David B. |
Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
|
US20040229839A1
(en)
|
2003-05-14 |
2004-11-18 |
Biocryst Pharmaceuticals, Inc. |
Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
|
WO2005020885A2
(en)
|
2003-05-21 |
2005-03-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
|
WO2004106356A1
(en)
|
2003-05-27 |
2004-12-09 |
Syddansk Universitet |
Functionalized nucleotide derivatives
|
UA82695C2
(uk)
|
2003-06-06 |
2008-05-12 |
Нисан Кемикал Индастриз, Лтд. |
Гетероароматичні сполуки як активатори рецептора тромбопоетину
|
US20070203083A1
(en)
|
2003-06-13 |
2007-08-30 |
Mootha Vamsi K |
Methods Of Regulating Metabolism And Mitochondrial Function
|
US20070042350A1
(en)
|
2003-07-14 |
2007-02-22 |
Ze Li |
Methods and compositions for detecting sars virus and other infectious agents
|
UY28423A1
(es)
|
2003-07-18 |
2005-02-28 |
Vertex Pharma |
Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
MXPA06002198A
(es)
|
2003-08-27 |
2007-08-14 |
Biota Scient Management |
Nucleosidos o nucleotidos triciclicos novedosos como agentes terapeuticos.
|
MY148123A
(en)
|
2003-09-05 |
2013-02-28 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
JP4685775B2
(ja)
|
2003-09-18 |
2011-05-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、とりわけhcvns3−ns4aプロテアーゼの阻害剤
|
JP2007509180A
(ja)
|
2003-10-21 |
2007-04-12 |
インスパイアー ファーマシューティカルズ,インコーポレイティド |
疼痛を治療するための、非ヌクレオチド組成物および方法
|
US7151089B2
(en)
|
2003-10-27 |
2006-12-19 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
JP2007514647A
(ja)
|
2003-10-21 |
2007-06-07 |
インスパイアー ファーマシューティカルズ,インコーポレイティド |
テトラヒドロ−フロ[3,4−d]ジオキソール化合物並びに血小板凝集を阻害する組成物及び方法
|
US7749981B2
(en)
|
2003-10-21 |
2010-07-06 |
Inspire Pharmaceuticals, Inc. |
Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
|
US7335648B2
(en)
|
2003-10-21 |
2008-02-26 |
Inspire Pharmaceuticals, Inc. |
Non-nucleotide composition and method for inhibiting platelet aggregation
|
US7504497B2
(en)
|
2003-10-21 |
2009-03-17 |
Inspire Pharmaceuticals, Inc. |
Orally bioavailable compounds and methods for inhibiting platelet aggregation
|
US20050239733A1
(en)
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
JP2005162732A
(ja)
|
2003-11-13 |
2005-06-23 |
Bayer Cropscience Ag |
殺虫性ニコチノイルカーバメート類
|
US20070238099A1
(en)
|
2003-12-08 |
2007-10-11 |
Cohen Irun R |
Antigen Receptor Variable Region Typing
|
EP2311851A3
(en)
|
2004-02-04 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
US20070276139A1
(en)
|
2004-02-10 |
2007-11-29 |
Quanlai Song |
Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis
|
EP2415481A3
(en)
|
2004-02-19 |
2012-04-18 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory viral RNA oligonucleotides
|
US8759317B2
(en)
|
2004-03-18 |
2014-06-24 |
University Of South Florida |
Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
|
EP2399924B1
(en)
|
2004-05-27 |
2015-01-28 |
Alnylam Pharmaceuticals, Inc. |
Nuclease resistant double-stranded ribonucleic acid
|
GB0413726D0
(en)
|
2004-06-18 |
2004-07-21 |
Lauras As |
Compounds
|
WO2006088490A2
(en)
|
2004-06-30 |
2006-08-24 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a non-phosphate backbone linkage
|
US7772271B2
(en)
|
2004-07-14 |
2010-08-10 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
BRPI0511834A
(pt)
|
2004-07-14 |
2008-01-08 |
Ptc Therapeutics Inc |
métodos por tratar hepatite c
|
CA2577526A1
(en)
|
2004-08-23 |
2006-03-02 |
Joseph Armstrong Martin |
Antiviral 4'-azido-nucleosides
|
WO2006028742A2
(en)
|
2004-09-01 |
2006-03-16 |
Dynavax Technologies Corporation |
Methods and conpositions for inhibition of innate immune responses and autoimmunity
|
RU2433124C2
(ru)
|
2004-09-14 |
2011-11-10 |
Фармассет, Инк. |
Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
|
US7553653B2
(en)
|
2004-09-17 |
2009-06-30 |
Biomarin Pharmaceutical Inc. |
Variants and chemically-modified variants of phenylalanine ammonia-lyase
|
NZ554214A
(en)
|
2004-09-24 |
2009-10-30 |
Alnylam Pharmaceuticals Inc |
Rnai modulation of apob and uses thereof
|
EP2374464A3
(en)
|
2004-10-01 |
2011-10-26 |
Vertex Pharmaceuticals Incorporated |
HCV N3S-NS4A protease inhibition
|
WO2006038865A1
(en)
|
2004-10-01 |
2006-04-13 |
Betagenon Ab |
Nucleotide derivatives for the treatment of type 2 diabetes and other disorders
|
CA2588979C
(en)
|
2004-12-08 |
2013-01-22 |
Nissan Chemical Industries, Ltd. |
3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
|
AU2005313883B2
(en)
|
2004-12-09 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
US7560544B2
(en)
|
2004-12-17 |
2009-07-14 |
Anadys Pharmaceuticals, Inc. |
3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
|
AU2005316503A1
(en)
|
2004-12-17 |
2006-06-22 |
Dynavax Technologies Corporation |
Methods and compositions for induction or promotion of immune tolerance
|
AU2006206267A1
(en)
|
2005-01-21 |
2006-07-27 |
Introgen Therapeutics, Inc. |
Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
|
US8802840B2
(en)
|
2005-03-08 |
2014-08-12 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
US7638488B2
(en)
|
2005-03-08 |
2009-12-29 |
Intermune, Inc. |
Use of alpha-glucosidase inhibitors to treat alphavirus infections
|
JP2006248949A
(ja)
|
2005-03-09 |
2006-09-21 |
Univ Nagoya |
ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法
|
JP2006248975A
(ja)
|
2005-03-10 |
2006-09-21 |
Tokyo Institute Of Technology |
ヌクレオシドホスホロアミダイト化合物
|
US20060229265A1
(en)
|
2005-03-30 |
2006-10-12 |
Sirtris Pharmaceuticals, Inc. |
Nicotinamide riboside and analogues thereof
|
ES2261072B1
(es)
|
2005-04-06 |
2007-12-16 |
Consejo Superior Investig. Cientificas |
Fosforotioatos derivados de analogos a nucleosido para terapia antirretroviral.
|
US20060240462A1
(en)
|
2005-04-21 |
2006-10-26 |
Johnson & Johnson Research Pty Limited |
Methods for amplification and detection of nucleic acids
|
CA2609342A1
(en)
|
2005-04-26 |
2006-11-02 |
Andrei L. Gartel |
Nucleoside compounds and methods of use thereof
|
WO2006121820A1
(en)
|
2005-05-05 |
2006-11-16 |
Valeant Research & Development |
Phosphoramidate prodrugs for treatment of viral infection
|
WO2007027248A2
(en)
|
2005-05-16 |
2007-03-08 |
Valeant Research & Development |
3', 5' - cyclic nucleoside analogues for treatment of hcv
|
WO2006130781A2
(en)
|
2005-06-01 |
2006-12-07 |
The Scripps Research Institute |
Crystal of a cytochrome-ligand complex and methods of use
|
US8143288B2
(en)
|
2005-06-06 |
2012-03-27 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
WO2007006544A2
(en)
|
2005-07-12 |
2007-01-18 |
Vrije Universiteit Brussel |
Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders
|
WO2007015757A2
(en)
|
2005-07-21 |
2007-02-08 |
Nereus Pharmaceuticals, Inc. |
Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators
|
US20070213292A1
(en)
|
2005-08-10 |
2007-09-13 |
The Rockefeller University |
Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
|
WO2007020018A1
(en)
|
2005-08-12 |
2007-02-22 |
Universite Libre De Bruxelles |
Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
|
CN101287472B
(zh)
|
2005-08-15 |
2011-10-12 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
|
TW200800213A
(en)
|
2005-09-02 |
2008-01-01 |
Abbott Lab |
Novel imidazo based heterocycles
|
AU2006302729B2
(en)
|
2005-10-07 |
2011-02-03 |
Speedx Pty Ltd |
Multicomponent nucleic acid enzymes and methods for their use
|
WO2007051303A1
(en)
|
2005-11-02 |
2007-05-10 |
Protiva Biotherapeutics, Inc. |
MODIFIED siRNA MOLECULES AND USES THEREOF
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
CA2626584A1
(en)
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
EP1974732A4
(en)
|
2005-11-24 |
2010-08-11 |
Univ Hokkaido Nat Univ Corp |
THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE
|
RU2422454C2
(ru)
|
2005-12-09 |
2011-06-27 |
Ф. Хоффманн-Ля Рош Аг |
Антивирусные нуклеозиды
|
US20090221684A1
(en)
|
2005-12-22 |
2009-09-03 |
Trustees Of Boston University |
Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof
|
EP1982174A4
(en)
|
2006-01-27 |
2009-05-06 |
Univ George Mason |
EYE LIQUID MARKERS
|
US7846908B2
(en)
|
2006-03-16 |
2010-12-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of TGF-beta and therapeutic uses thereof
|
US7718629B2
(en)
|
2006-03-31 |
2010-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 gene
|
FR2900334B1
(fr)
|
2006-04-28 |
2008-06-27 |
Oreal |
Procede de depigmentation de la peau
|
WO2007130783A2
(en)
|
2006-05-03 |
2007-11-15 |
Chimerix, Inc. |
Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
|
WO2007149554A2
(en)
|
2006-06-22 |
2007-12-27 |
The Johns Hopkins University |
Methods for restoring neural function
|
US8470522B2
(en)
|
2006-07-20 |
2013-06-25 |
Kaohsiung Medical University |
Three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes and preparation process and uses of the same
|
WO2008039267A2
(en)
|
2006-07-21 |
2008-04-03 |
Pharmexa Inc. |
Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
|
US7659270B2
(en)
|
2006-08-11 |
2010-02-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7759495B2
(en)
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2008024977A2
(en)
|
2006-08-24 |
2008-02-28 |
Serenex, Inc. |
Isoquinoline, quinazoline and phthalazine derivatives
|
EP2465855A1
(en)
|
2006-08-31 |
2012-06-20 |
Abbott Laboratories |
Cytochrome P450 oxidase inhibitors and uses thereof
|
WO2008033432A2
(en)
|
2006-09-12 |
2008-03-20 |
Coley Pharmaceutical Group, Inc. |
Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
|
US20080161324A1
(en)
|
2006-09-14 |
2008-07-03 |
Johansen Lisa M |
Compositions and methods for treatment of viral diseases
|
GB0618235D0
(en)
|
2006-09-15 |
2006-10-25 |
Lauras As |
Process
|
AP2009004812A0
(en)
|
2006-10-10 |
2009-04-30 |
Medivir Ab |
HCV nucleoside inhibitor
|
PL216525B1
(pl)
|
2006-10-17 |
2014-04-30 |
Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk |
5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
ES2454175T3
(es)
|
2006-11-09 |
2014-04-09 |
Dynavax Technologies Corporation |
Modificación de una enfermedad a largo plazo mediante el uso de oligonucleótidos inmunoestimuladores
|
US7598040B2
(en)
|
2006-11-22 |
2009-10-06 |
Trana Discovery, Inc. |
Compositions and methods for the identification of inhibitors of protein synthesis
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
EP2124555B1
(en)
|
2007-01-05 |
2015-07-08 |
Merck Sharp & Dohme Corp. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
AU2008210411A1
(en)
|
2007-01-31 |
2008-08-07 |
Alios Biopharma, Inc. |
2-5A derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents
|
US20100190837A1
(en)
|
2007-02-15 |
2010-07-29 |
Isis Pharmaceuticals, Inc. |
5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
|
EP2131848A4
(en)
|
2007-02-16 |
2012-06-27 |
Merck Sharp & Dohme |
COMPOSITIONS AND METHODS FOR POTENTIATING THE ACTIVITY OF BIOLOGICALLY ACTIVE MOLECULES
|
US8242087B2
(en)
|
2007-02-27 |
2012-08-14 |
K.U.Leuven Research & Development |
Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
|
US20120108533A1
(en)
|
2007-02-27 |
2012-05-03 |
Katholieke Universiteit Leuven, K.U.Leuven R&D |
Novel phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
|
EP2144921A2
(en)
|
2007-02-27 |
2010-01-20 |
K.U. Leuven Research and Development |
Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
|
MX2009009530A
(es)
|
2007-03-07 |
2010-05-19 |
Nventa Biopharmaceuticals Corp |
Composiciones de acidos nucleicos cerrados bicatenarios.
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
US7741347B2
(en)
|
2007-05-17 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB0709791D0
(en)
|
2007-05-22 |
2007-06-27 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
PL211703B1
(pl)
|
2007-07-03 |
2012-06-29 |
Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk |
Tiohypofosforanowe i ditiohypofosforanowe analogi 5'-O-hypofosforanów nukleozydów i ich estry alkilowe oraz sposób ich wytwarzania
|
CN101108870A
(zh)
|
2007-08-03 |
2008-01-23 |
冷一欣 |
核苷磷酸酯类化合物及制备方法和应用
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
US7728027B2
(en)
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US20090318380A1
(en)
|
2007-11-20 |
2009-12-24 |
Pharmasset, Inc. |
2',4'-substituted nucleosides as antiviral agents
|
BRPI0821106A2
(pt)
|
2007-11-29 |
2015-06-16 |
Ligand Pharm Inc |
Pró-fármacos de nucleosídeo e usos dos mesmos
|
WO2009086201A1
(en)
|
2007-12-21 |
2009-07-09 |
Alios Biopharma, Inc. |
2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents
|
US20090176732A1
(en)
|
2007-12-21 |
2009-07-09 |
Alios Biopharma Inc. |
Protected nucleotide analogs
|
WO2009102318A1
(en)
|
2008-02-12 |
2009-08-20 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US8147818B2
(en)
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7704992B2
(en)
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
SI2242752T1
(sl)
|
2008-02-13 |
2013-03-29 |
Bristol-Myers Squibb Company |
Imidazolil bifnil imidazoli kot hepatitis c virusni inhibitorji
|
GB2471806B
(en)
|
2008-04-03 |
2012-12-19 |
Spring Bank Pharmaceuticals Inc |
Compositions and methods for treating viral infections
|
EP3042660A3
(en)
|
2008-04-15 |
2016-10-26 |
RFS Pharma, LLC. |
Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
US7906655B2
(en)
|
2008-08-07 |
2011-03-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR101726282B1
(ko)
|
2008-08-15 |
2017-04-12 |
더 유에이비 리서치 파운데이션 |
뉴클레오시드 프로드럭의 효소 활성자로서의 퓨린 뉴클레오시드 인산화효소
|
GB0815315D0
(en)
|
2008-08-21 |
2008-09-24 |
Univ Leiden |
Organ protection
|
WO2010030858A1
(en)
|
2008-09-15 |
2010-03-18 |
Enanta Pharmaceuticals, Inc. |
4'-allene-substituted nucleoside derivatives
|
WO2010048549A2
(en)
|
2008-10-24 |
2010-04-29 |
Isis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
WO2010062821A1
(en)
|
2008-11-28 |
2010-06-03 |
Glaxosmithkline Llc |
Anti-viral compounds, compositions, and methods of use
|
BRPI0922364A2
(pt)
|
2008-12-03 |
2017-08-29 |
Presidio Pharmaceuticals Inc |
Composto, composição farmacêutica e uso de um composto
|
AU2009322393B2
(en)
|
2008-12-03 |
2017-02-02 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of HCV NS5A
|
WO2010091386A2
(en)
|
2009-02-06 |
2010-08-12 |
Rfs Pharma, Llc |
Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
|
WO2010091413A1
(en)
|
2009-02-09 |
2010-08-12 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
WO2010096462A1
(en)
|
2009-02-17 |
2010-08-26 |
Enanta Pharmaceuticals, Inc |
Linked diimidazole derivatives
|
TWI438200B
(zh)
|
2009-02-17 |
2014-05-21 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
CA2753313A1
(en)
|
2009-02-23 |
2010-08-26 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
SG174146A1
(en)
|
2009-02-27 |
2011-10-28 |
Enanta Pharm Inc |
Hepatitis c virus inhibitors
|
KR20110128947A
(ko)
|
2009-03-20 |
2011-11-30 |
앨리오스 바이오파마 인크. |
치환된 뉴클레오시드 및 뉴클레오티드 유사체
|
SG10201402969QA
(en)
|
2009-03-27 |
2014-09-26 |
Merck Sharp & Dohme |
Inhibitors of hepatitis c virus replication
|
US8796466B2
(en)
|
2009-03-30 |
2014-08-05 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TWI476190B
(zh)
|
2009-03-30 |
2015-03-11 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
TW201038559A
(en)
|
2009-04-09 |
2010-11-01 |
Bristol Myers Squibb Co |
Hepatitis C virus inhibitors
|
US8143414B2
(en)
|
2009-04-13 |
2012-03-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
MX2011010905A
(es)
|
2009-04-15 |
2011-11-01 |
Abbott Lab |
Compuestos antivirales.
|
US8436036B2
(en)
|
2009-04-24 |
2013-05-07 |
Janssen R&D Ireland |
Diaryl ethers
|
US20120196919A1
(en)
|
2009-04-28 |
2012-08-02 |
New York University |
Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
|
WO2010132538A1
(en)
|
2009-05-12 |
2010-11-18 |
Schering Corporation |
Fused tricyclic aryl compounds useful for the treatment of viral diseases
|
US20100297079A1
(en)
|
2009-05-20 |
2010-11-25 |
Chimerix, Inc. |
Compounds, compositions and methods for treating viral infection
|
US20100331397A1
(en)
|
2009-06-24 |
2010-12-30 |
Alios Biopharma, Inc. |
2-5a analogs and their methods of use
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
RU2012136824A
(ru)
|
2010-01-29 |
2014-03-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способы лечения вирусной инфекции гепатита с
|
UY33445A
(es)
|
2010-06-10 |
2012-01-31 |
Gilead Sciences Inc |
Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit
|
EP2611451A4
(en)
*
|
2010-08-30 |
2014-01-15 |
Spring Bank Pharmaceuticals Inc |
DESIGN OF OLIGONUCLEOTIDE ANALOGUES AS THERAPEUTIC AGENTS
|
WO2012040126A1
(en)
|
2010-09-22 |
2012-03-29 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
PE20140608A1
(es)
*
|
2010-09-22 |
2014-06-12 |
Alios Biopharma Inc |
Analogos de nucleotidos sustituidos
|
WO2012040124A1
(en)
|
2010-09-22 |
2012-03-29 |
Alios Biopharma, Inc. |
Azido nucleosides and nucleotide analogs
|
AU2011349278C1
(en)
|
2010-12-22 |
2017-01-19 |
Alios Biopharma, Inc. |
Cyclic nucleotide analogs
|
BR112013026345A2
(pt)
|
2011-04-13 |
2019-04-24 |
Merck Sharp & Dohe Corp. |
composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
|
EP2794630A4
(en)
*
|
2011-12-22 |
2015-04-01 |
Alios Biopharma Inc |
SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
|
PL2794627T3
(pl)
|
2011-12-22 |
2019-04-30 |
Alios Biopharma Inc |
Podstawione nukleozydy, nukleotydy i ich analogi
|
WO2013142159A1
(en)
|
2012-03-21 |
2013-09-26 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
NZ630800A
(en)
|
2012-03-21 |
2016-06-24 |
Alios Biopharma Inc |
Methods of preparing substituted nucleotide analogs
|
NZ629428A
(en)
|
2012-03-21 |
2016-10-28 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
NZ631601A
(en)
*
|
2012-03-21 |
2016-06-24 |
Alios Biopharma Inc |
Solid forms of a thiophosphoramidate nucleotide prodrug
|
WO2013142157A1
(en)
|
2012-03-22 |
2013-09-26 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
KR102327888B1
(ko)
|
2012-12-21 |
2021-11-17 |
얀센 바이오파마, 인코퍼레이트. |
치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
|
WO2014100498A1
(en)
|
2012-12-21 |
2014-06-26 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|